Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sandoz Olaparib vs Lynparza in Patients with Ovarian or Breast Cancer
NCT05258747Phase 1Completed
- Sponsor
- Sandoz
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in ovarian cancer and breast cancer (2 arms), sponsored by Sandoz. Primary endpoints: Maximum Plasma Concentration During the Dosing Interval at Steady State at Day 16 and Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State at Day 16. Started Apr 2022; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT05258747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258747.